BPC-157 may not be appropriate when: Imaging or specialist review has not yet been completed for a suspected structural injury There are acute red flag features (severe weakness, fever, rapid unexplained swelling, neurological changes, unexplained weight loss) The patient has active cancer or a history of certain cancers where angiogenic peptides require careful risk assessment The goal is rapid results without addressing underlying load, rehabilitation, or lifestyle drivers A peptide should not be used to delay evaluation that is clearly warranted
However, recent clinical evidence suggests the picture is more nuanced than previously understood
The shelf life of semaglutide depends on whether the medication remains unopened or has been used, with specific timeframes established through FDA-approved stability testing
Our services include: Peptide therapy , including BPC-157 Stem cell therapy , using ethically sourced umbilical cord stem cells Customized regenerative programs to support joint health, performance, and long-term vitality Our team of experienced providers ensures every treatment is tailored to your specific needs with full transparency about whats being used, how it works, and how it fits into your health goals
They are not approved for human or veterinary use, consumption, or therapeutic application
As of 2026, the FDA has not approved any therapeutic peptides for musculoskeletal or orthopedic applications
